Neurofibromatosis type 1 is an autosomal-dominant disorder affecting approximately 1 in 3500 births. It is characterized by café-au-lait spots, neurofibromas, axillary/inguinal freckling, and skeletal and neurologic signs. It exhibits full penetrance and a high mutation rate: 50% of neurofibromatosis type 1 patients represent a new mutation. The gene, located at 17q11.2, contains 60 exons that encode a 11-13-kb mRNA transcript. The mutation rate for neurofibromatosis type 1 is one of the highest known for human disorders, probably because of the large size of the gene, gene conversions mediated by pseudogenes, and the presence of repeated sequences. No clear genotype-phenotype correlation is established, except for patients with deletion of the entire neurofibromatosis type 1 gene. Neurofibromatosis type 1 mutations seem to be equally distributed along the gene. However, some exons in the neurofibromatosis type 1 gene may have a higher mutation rate, and the majority of these mutations are recurrent. We analyzed five exons (exons 4b, 16, 29, 31, and 37) for recurrent mutations and unknown mutations in 100 Turkish patients with neurofibromatosis type 1. We identified 496delGT and 499delTGTT mutations in exon 4b and 5866delA as a new mutation in exon 31 (Human Gene Mutation Database accession number Hd0524).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pediatrneurol.2007.07.005 | DOI Listing |
J Neurol Surg B Skull Base
February 2025
Department of Neurosurgery, UC San Diego Medical Center, San Diego, California, United States.
Many patients with neurofibromatosis type 2 (NF2) suffer from sensorineural hearing loss, and associated cochlear nerve compromise in NF2 patients makes auditory brainstem implant (ABI) an attractive treatment option. The long-term outcomes and benefits of the device are still being explored. A retrospective review was conducted for 11 ABI recipients at a single-institution tertiary center between November 2017 and August 2022.
View Article and Find Full Text PDFChirurgie (Heidelb)
January 2025
Universitätsklinik für Plastische, Rekonstruktive und Ästhetische Chirurgie, Medizinische Universität Wien, Wien, Österreich.
Neurofibromatosis type 1 (NF1, formerly Recklinghausen's disease) is a genetic tumor predisposition syndrome in which the mutation of a tumor suppressor gene (neurofibromin) leads to the development of mostly benign neurofibromas of the skin and the central and peripheral nervous systems and malformations or tumors of other organ systems. Patients with NF1 should receive lifelong interdisciplinary care in specialized centers and important treatment decisions should be made by a regularly meeting interdisciplinary panel of experts. Plastic surgery plays an important role in the multidisciplinary management of all clinical forms of NF1-associated peripheral nerve sheath tumors, from cutaneous and subcutaneous to deep nodular and diffuse plexiform neurofibromas.
View Article and Find Full Text PDFNeuro Oncol
January 2025
Department of Neurology, Division of Infectious Diseases, Washington University School of Medicine, St. Louis MO 63110 USA.
Background: The intestinal microbiota regulates normal brain physiology and the pathogenesis of several neurological disorders. While prior studies suggested that this regulation operates through immune cells, the underlying mechanisms remain unclear. Leveraging two well characterized murine models of low-grade glioma (LGG) occurring in the setting of the neurofibromatosis type 1 (NF1) cancer predisposition syndrome, we sought to determine the impact of the gut microbiome on optic glioma progression.
View Article and Find Full Text PDFJ Cutan Med Surg
January 2025
Division of Dermatology, McGill University, Montreal, QC, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!